{
    "Trade/Device Name(s)": [
        "Dexcom G6 Continuous Glucose Monitoring (CGM) System"
    ],
    "Submitter Information": "Dexcom, Inc.",
    "510(k) Number": "K223931",
    "Predicate Device Reference 510(k) Number(s)": [
        "K221259",
        "DEN170088",
        "K213919"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ"
    ],
    "Summary Letter Date": "December 29, 2022",
    "Summary Letter Received Date": "December 30, 2022",
    "Submission Date": "January 4, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dexcom G6 sensor/applicator",
        "Dexcom Bluetooth Low Energy transmitter",
        "Dexcom receiver",
        "Mobile application (Android OS and Apple iOS)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy wireless data transmission"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Transmitter",
        "Receiver",
        "Mobile application"
    ],
    "Document Summary": "FDA 510(k) summary for Dexcom G6 Continuous Glucose Monitoring System with alternative receiver for diabetes management using interstitial glucose monitoring",
    "Indications for Use Summary": "Real-time continuous glucose monitoring device indicated for management of diabetes in persons age 2 years and older, replacing fingerstick blood glucose testing and communicating with connected devices including automated insulin dosing systems",
    "fda_folder": "Clinical Chemistry"
}